Results 101 to 110 of about 14,735 (228)

Pharmacokinetics of Rosiglitazone According to CYP2C8 Genotype in Korean Population [PDF]

, 2005
Joo‐Youn Cho, Hyeong-Seok Lim, You-Sin Suh, Jae‐Yong Chung, Kyoung-Sup Hong, So-Young Yi, Kyung‐Sang Yu, In‐Jin Jang, Sang-Goo Shin   +8 more
openalex   +1 more source

Distribution of Genetic Polymorphisms in Drug Metabolizing Gene Cytochrome P450 (CYP2C8*3 and CYP2C9*2) in a North Indian Type 2 Diabetes Population [PDF]

, 2016
Farzana Mahdi, Syed Tasleem Raza, Saliha Rizvi, Shania Abbas, Ritu Karoli, Syed Tasleem Raza, W Evans, H Mcleod, U Glamolija, A Jevri-auevi, T Lynch, A Price, R Slaughter, D Edwards, G Wilkinson, K Phillips, D Veenstra, Oren Lee, J Sadee, W, L Bradford, S Semiz, T Dujic, B Ostanek, B Prnjavorac, T Bego, M Malenica, G Umamaheswaran, D Kumar, C Adithan, C Lee, J Goldstein, J Pieper, W Friedewald, R Levy, D Fredrickson, U Meyer, D Dai, D Zeldin, J Blaisdell, B Chanas, S Coulter, B Ghanayem, T Yoko, N Bahadur, Jbs Leathart, E Mutch, D Steimel-Crespi, S Dunn, R Gilissen, M Niemi, J Leathart, M Neuvonen, J Backman, A Daly, P Neuvonen, U Yasar, S Lundgren, E Eliasson, A Bennet, B Wiman, U De Faire, C Martnez, E Garca-Martn, G Blanco, F Gamito, J Ladero, J Agndez, Y Saab, T Langaee, Si1 Hamdy, M Hiratsuka, K Narahara, M El-Enany, N Moursi, M Ahmed, T Sullivan-Klose, B Ghanayem, D Bell, Z Zhang, L Kaminsky, G Shenfield, M Stubbins, L Harries, G Smith, M Tarbit, C Wolf, U Yasar, E Eliasson, M Dahl, I Johansson, M Ingelman-Sundberg, F Sjqvist, A Aynacioglu, J Brockmller, S Bauer, C Sachse, P Gzelbey, Z Ongen, K Nasu   +99 more
openalex   +1 more source

In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity [PDF]

, 2016
Johan Monbaliu, Martha Gonzalez, Apexa Bernard, James Jiao, Carlo Sensenhauser, Jan Snoeys, Hans Stieltjes, Inneke Wynant, Johan W. Smit, Caly Chien   +9 more
openalex   +1 more source

Effect of Myricetin on CYP2C8 Inhibition to Assess the Likelihood of Drug Interaction Using In Silico, In Vitro, and In Vivo Approaches

, 2022
Shipra Bhatt, Diksha Manhas, Vinay Kumar, Abhishek Gour, Kuhu Sharma, Ashish Dogra, Probir Kumar Ojha, Utpal Nandi   +7 more
openalex   +1 more source

Cytochrome P450 enzymes [PDF]

, 2017
No abstract ...
Meyer, Urs A.
core  

The Role of CYP3A4 and CYP2C8 Polymorphism on Amiodarone Responses: Review Article [PDF]

, 2023
EM Sutrisna
openalex   +1 more source

Modeling and predicting drug pharmacokinetics in patients with renal impairment

, 2011
Current guidance issued by the US FDA to assess the impact of renal impairment on the pharmacokinetics of a drug under development has recently been updated to include evaluation of drugs with nonrenal elimination routes.
Aarabi, M., Jamei, M., Rostami-Hodjegan, A., Rowland Yeo, K.   +3 more
core   +1 more source

Downregulation of CYP2A6 and CYP2C8 in Tumor Tissues Is Linked to Worse Overall Survival and Recurrence-Free Survival from Hepatocellular Carcinoma [PDF]

, 2018
Xiaojing Ren, Yuanyuan Ji, Xuhua Jiang, Xun Qi   +3 more
openalex   +1 more source

Influence ofCYP2C8*13andCYP2C8*14Alleles on AmiodaroneN‐Deethylation [PDF]

Basic & Clinical Pharmacology & Toxicology, 2011
Nobumitsu, Hanioka, Kimiaki, Matsumoto, Yoshiro, Saito, Shizuo, Narimatsu   +3 more
openaire   +2 more sources

CYP2C8-Mediated Drug–Drug Interactions and the Factors Influencing the Interaction Magnitude

Drug Design, Development and Therapy
Ling-Ling Zhu,1,* Ling-Yan Yu,2,* Yan-Hong Wang,2 Quan Zhou2 1VIP Care and Geriatric Ward, Division of Nursing, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People’s Republic of ...
Zhu LL, Yu LY, Wang YH, Zhou Q
doaj